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Abstract: Overactive bladder syndrome (OAB) is a constellation of distressing symptoms 
that signiﬁ  cantly impair quality of life, sexual function, and work productivity, and imposes a 
signiﬁ  cant economic burden to society. Pharmacological treatment with antimuscarinic agents, 
behavioral modiﬁ  cation, bladder retraining, and/or pelvic ﬂ  oor exercises are often used alone 
or in combination as the mainstay treatment in the management of OAB. Oxybutynin has been 
used in the treatment of OAB for over 20 years with proven efﬁ  cacy and is often the comparator 
in drug treatment trials. Oral formulations of oxybutynin have proven efﬁ  cacy, but not without 
signiﬁ  cant antimuscarinic effects, which reduce patient persistence with medical treatment. Low 
levels of patient persistence with oral formulations of oxybutynin provided an impetus for the 
development of a transdermal oxybutynin delivery system. The oxybutynin transdermal formula-
tion has been found to have side effects similar to that of a placebo in randomized controlled trials 
while providing excellent efﬁ  cacy. Patient persistence with therapy, improved quality of life, 
sexual function and interpersonal relationships have been observed with use of the transdermal 
oxybutynin delivery system. Its twice weekly dosing, low side effect proﬁ  le, and high efﬁ  cacy 
have made it a good choice for initial treatment of overactive bladder syndrome.
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Introduction
Overactive bladder syndrome (OAB) is a highly prevalent condition in the USA 
affecting up to17% or approximately 33 million adults with 12 million experiencing 
urge urinary incontinence (UUI) (Milsom et al 2000; Voytas 2002; Stewart et al 2003). 
UUI increases with age and affects 6.3 million community-dwelling senior citizens 
and 1.2 million nursing home inhabitants (Milsom et al 2000). In 2003, the National 
Overactive Bladder Evaluation program, which examined the prevalence of OAB and 
its impact in the US, demonstrated that 16% of men and 16.9% of women suffered 
from OAB. This is similar to the prevalence in Europe (Milsom et al 2001; Irwin et al 
2006, 2008). This distressing condition is known to have an adverse effect on quality 
of life, sexual function, and work productivity (Wagner et al 2002; Lavelle et al 2006). 
Other health- related consequences include increased urinary tract infections, falls 
and fractures, and a reason for up to 50% of nursing home admissions (Voytas 2002; 
Wagner et al 2002; Hu and Wagner 2005). OAB can lead to depression, anxiety, social 
isolation and sleep deprivation (Wagner et al 2002; Stewart et al 2003; Sand et al 2007). 
Aside from health-related consequences, OAB poses a signiﬁ  cant economic burden to 
society. Annual costs estimates are over US$9 billion per year with US$2.9, US$1.5 
and US$3.9 billion for diagnosis and treatment, routine care and treatment for other 
health-related consequences, respectively (Hu and Wagner 2005). An over US$800 
million loss in work productivity has been reported because of fatigue and distraction 
resulting from symptoms of urgency, frequency, nocturia and sleep disturbances 
(Hu and Wagner 2005). The impact of this condition on society is profound.Patient Preference and Adherence 2008:2 350
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Urgency is the cardinal symptom of OAB, which is 
usually accompanied by frequency and nocturia with 
or without urge urinary incontinence (UUI). Detrusor 
overactivity or involuntary bladder contractions is the most 
common reason for UUI and OAB, and is the primary cause 
of urinary incontinence in older individuals (Gibbs et al 
2007). Unstable detrusor contractions usually are symptom-
atic causing patients to complain of severe urgency, which 
is deﬁ  ned as a sudden, compelling desire to urinate that is 
difﬁ  cult to defer, which is often accompanied by UUI where 
patients leak urine before reaching the toilet. Although neuro-
genic processes such as Parkinson’s disease, cerebrovascular 
accidents, and multiple sclerosis are known etiologies, 90% 
of detrusor overactivity is idiopathic. The origin as well as 
pathophysiology of detrusor overactivity is multifactorial 
and often difﬁ  cult to fully explain.
Pathophysiology
OAB is a very distressing condition and remains an enigma in 
regard to its pathophysiology. The etiology of OAB is likely 
to be multifactorial involving multiple interrelated processes. 
CNS and/or peripheral nervous system abnormalities, abnor-
malities of the bladder urothelium and/or the detrusor muscle 
have all been implicated (Goldberg and Sand 2002; Birder 
2005; Fabiyi and Brading 2006; Brading 2007). Both afferent 
and efferent neural pathways are involved in the regulation 
of normal mictrurition, and these are controlled by a variety 
of central and peripheral neurotransmitters. Acetylcholine, 
which binds to muscarinic receptors in the detrusor muscle 
to effect bladder contractions, is one of the most common 
neurotransmitters. The M3 receptors in the detrusor muscle 
are primarily responsible for normal detrusor activity and 
M3 receptors in the urothelium may regulate afferent sensa-
tion (Scarpero and Dmochowski 2003). Afferent nerves are 
known to lie in proximity to the urothelium and are involved 
in sensory feedback to the brain (Andersson 2002; Ouslander 
2004; Birder 2005; De Laet et al 2006). Derangements in the 
structure or function of the sensory afferent nerves to the 
urinary bladder or abnormalities in the sensory feed back 
mechanisms that regulate the normal mictrurition process 
may result in the symptoms of OAB.
Pharmacological treatment with antimuscarinic agents 
and behavioral modiﬁ  cation are often used alone or in com-
bination in the management of OAB (Burgio et al 2000). 
Drugs that have high afﬁ  nity for M3 receptors may offer a 
therapeutic advantage in the treatment in OAB. Although 
M3 receptors are less numerous in the detrusor muscle 
than M2 receptors, M3 receptors are primarily responsible 
for activating detrusor contractions and often interact with 
M2 receptors in pathologic states. However, drugs that act on 
muscarinic receptors may also affect receptors in other body 
organs such as the salivary glands, brain, eye, and gastroin-
testinal tract. These agents can cause signiﬁ  cant side effects 
such as dry mouth, constipation, visual and CNS disturbances 
which can preclude patient compliance with their use. To con-
tend with the adverse effects of antimuscarinic medications, 
various pharmacological agents with selective afﬁ  nity to 
bladder M2 and M3 receptors and agents with different 
delivery systems have been developed.
The efﬁ  cacy of these agents lies in their ability to 
inhibit involuntary detrusor contractions through blocking 
muscarinic receptors within the detrusor smooth muscle, 
urothelial presynaptic nerve terminals, and possibly at sen-
sory afferent nerve terminals in or beneath the urothelium 
itself (Chapple 2000; Andersson and Yoshida 2003; Kumar 
et al 2005). Antimuscarinic agents mitigate the sensation 
of urgency by also acting on sensory afferents within the 
bladder urothelium and increase the storage phase of the 
bladder cycle. Specifically, the antimuscarinic oxybu-
tynin decreases afferent nerve activity in C-ﬁ  ber bladder 
bladder afferents (De Laet et al 2006). Although the 3rd 
International Consultation on Incontinence gave a grade 
A recommendation to six different pharmacologic agents 
for OAB, oxybutynin transdermal is the primary focus of 
this review (Andersson et al 1999).
Oxybutynin has been used in the treatment of OAB for 
over 30 years with proven efﬁ  cacy and is often the drug 
against which new treatments are compared (Thuroff et al 
1991; Anderson et al 1999). Oxybutynin hydrochloride is 
a tertiary amine that has been widely used in the treatment 
of overactive bladder syndrome. Antimuscarinic action 
on M2 and M3 receptors impart smooth muscle relaxant 
effects as well as anesthetic capabilities (Hegde 2006). It is 
commercially available as an immediate (IR) or extended 
release (ER) oral form and a transdermal patch. Intra-
vesical instillations and rectal suppositories have also been 
investigated (Winkler and Sand 1998).
Review of pharmacology 
and pharmacokinetics
Oxybutynin undergoes extensive metabolism in the liver by 
the cytochrome P450 (CYP) enzyme system and principally 
CYP 3A4. It has a bioavailability of 6% and is metabo-
lized in the gut and liver after oral dosing to its primary 
metabolite N-desethyloxybutynin (N-DEO). N-DEO is 
a pharmacologically active metabolite which produces a Patient Preference and Adherence 2008:2 351
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wide range of systemic side effects which often reduce 
patient persistence on oral formulations of oxybutynin IR 
(Chancellor et al 2001; Appell et al 2003). In oxybutynin 
ER and oxybutynin IR, N-DEO circulates at concentration 
levels 4 and 10 times as high as the parent compound, 
respectively (Staskin 2003).
Untoward side effects are reduced with the oral 
extended-release formulation, which provides once daily 
dosing and improves patient persistence on therapy. The 
delivery system consists of an osmotic bilayer laser-drilled 
drug core with a delivery oriﬁ  ce which allows drug to be 
released at a controlled rate over 24 hours (Portera and 
Lipscomb 1998). The extended release formulation produces 
a more stable plasma level with absorption primarily in the 
colon diminishing ﬁ  rst pass metabolism in the upper gastro-
intestinal tract. The plasma level of the metabolite N-DEO 
plasma levels are reduced by 69% when compared with 
immediate release formulations (Oki et al 2006). However, 
signiﬁ  cant dry mouth remains due to N-DEO’s purported 
higher afﬁ  nity than oxybutynin, to the M3 receptors in the 
submaxillary gland (Oki et al 2006). Oral oxybutynin pro-
duces longer-lasting blockage of the muscarinic receptors 
abolishing the secretory response in the salivary glands 
which does not occur to the same degree with transdermal 
oxybutynin (Oki et al 2006).
The oxybutynin transdermal delivery system was 
developed to reduce ﬁ  rst pass metabolism thereby minimiz-
ing side effects. Transdermal oxybutynin administration 
results in greater systemic availability of oxybutynin and 
minimizes ﬁ  rst-pass metabolism to N-DEO compared with 
extended-release and immediate-release oral administration. 
The plasma metabolite N-DEO to oxybutynin ratio with the 
transdermal oxybutynin system is 1.2:1 compared to 4.1:1 
in the oral formulation (Appell et al 2003). Lower N-DEO 
plasma concentration and greater salivary gland output during 
transdermal oxybutynin treatment provide a low incidence 
of dry mouth in patients with overactive bladder syndrome 
(Appell et al 2003). In a double-blind, randomized trial 
comparing placebo to transdermal oxybutynin in the treat-
ment of patients with UUI and OAB, there was no signiﬁ  cant 
difference between the placebo and transdermal oxybutynin, 
in the incidence of constipation, dry mouth, CNS impairment, 
or visual changes (Dmochowski et al 2002).
Oxybutynin is an ideal compound for a transdermal 
formulation because it is a weak base (pKa = 8) and the free 
base form exists at physiologic pH, allowing transdermal 
permeation (Staskin 2003). The oxybutynin transdermal 
system is 39 cm2 with a three-layer matrix delivery system 
containing oxybutynin and a skin permeation enhancer 
triacetin, which are dissolved in an acrylic block-copolymer 
adhesive that continuously delivers oxybutynin for 3 to 4 days 
(Zobrist et al 2003). Oxybutynin passively diffuses across the 
skin into the systemic circulation. Following the application 
of the ﬁ  rst transdermal oxybutynin 3.9 mg/day system, 
oxybutynin plasma concentration increases for approximately 
24 to 48 hours, reaching an average maximum concentration 
of 3 to 4 ng/mL. Steady concentrations are maintained for 
up to 96 hours until the second application when it is widely 
distributed throughout body tissues. Following the removal 
of the transdermal system, plasma levels of both oxybutynin 
and N-DEO fall rapidly. It has a 7- to 8-hour half-life. The 
transdermal oxybutynin delivery system offers the advantage 
of much lower active metabolite concentrations of N-DEO 
due to its unique mode of delivery (Oxytrol PI 2003).
There are fewer CYP3A4 isoenzymes in the skin than in 
the liver or intestine, markedly reducing N-DEO metabolite 
serum levels when using the transdermal delivery system. 
This difference in metabolism signiﬁ  cantly increases the 
bioavailability of oxybutynin to 80%. This decrease in 
N-DEO levels reduces side effects and potentially improves 
patient persistence on therapy (Sahai et al 2008). The 
transdermal system contains 36 mg of oxybutynin and 
provides a consistent plasma drug level while delivering 
approximately 3.9 mg of oxybutynin/day. This leads to 
serum oxybutynin levels similar to those achieved with the 
10 mg oral extended-release formulation (Appell et al 2003). 
The oxybutynin transdermal delivery system has equivalent 
bioavailability when applied to the hip, abdomen, or buttock. 
Its position should be alternated to avoid occluding the same 
area of skin repetitively over a short period of time. Potential 
therapeutic beneﬁ  ts of transdermal delivery of oxybutynin 
in include greater saliva production, decreased peak and 
trough oxybutynin serum levels, decreased serum levels 
of the N-DEO metabolite, and greatly reduced ﬁ  rst pass 
metabolism (Appell et al 2003; Zobrist et al 2003). Also 
transdermal systems deliver the drug at a predetermined rate 
consistent with zero order kinetics which produces stable 
drug plasma concentrations (Staskin 2003; Davila et al 2006). 
Transdermal delivery systems also offer the advantage of 
steady state serum levels avoiding drug peaks and troughs, 
which worsen adverse effects at the peak and loss of efﬁ  cacy 
at the trough of serum oxybutynin levels. The bioavail-
ability of oxybutynin in the serum is also increased which 
may reduce the dosage needed to treat OAB symptoms. 
Further, because there is a higher prevalence of OAB in the 
elderly who are on multiple oral medications, the transdermal Patient Preference and Adherence 2008:2 352
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route may provide an attractive alternative for patients who 
do not want to take more oral medications.
Efﬁ  cacy and comparative studies
Davila et al (2001) showed that individuals who were 
randomized to oxybutynin transdermal versus oxybutynin 
immediate-release in a Phase 2 randomized trial demonstrated 
similar efﬁ  cacy. Nearly equal reductions in the average 
number of incontinence episodes/day: 7.3 and 7.4 epi-
sodes decreased to 2.4 and 2.6 (p  0.0001) in the 
oxybutynin transdermal versus oxybutynin immediate-
release, respectively. Further analysis using visual analog 
scales revealed improved scores in both the transdermal 
and oral oxybutynin group and no difference in subjective 
continence scores. An increase in average bladder volume 
at first detrusor contraction and increase in maximum 
cystometric capacity was not signiﬁ  cantly different between 
oral and transdermal oxybutynin. There was an increase in 
maximum cystometric capacity of 66 mL in the transdermal 
oxybutynin group (p = 0.0055) and 45 mL in the oral imme-
diate-release (p = 0.1428) (Davila et al 2001). Mean maxi-
mum cystometric capacity was increased by 51 ± 138 ml 
(p = 0.0538) in the oral and 53 ± 88ml (p = 0.0011) in 
the transdermal group. As anticipated, individuals given 
transdermal oxybutynin had signiﬁ  cantly less dry mouth 
over immediate-release oral oxybutynin (38% versus 94% 
respectively, p  0.0001). Further efﬁ  cacy of transdermal 
oxybutynin was provided in a phase IIIb trial using 
tolterodine extended-release 4 mg versus transdermal 
oxybutynin 3.9 mg/day. Both agents were found to decrease 
incontinence episodes, increase volume voided, and equally 
improve quality of life (Dmochowski et al 2003).
In a 12-week, double-blind randomized dose-ranging trial, 
520 individuals were randomized to 3 doses of transdermal 
oxybutynin versus placebo; 447 (86%) completed the initial 
double-blind treatment period and 358 (87.1%) completing 
the open-label study. Those who received 3.9 mg/day 
transdermal oxybutynin had signiﬁ  cant reductions in urinary 
frequency and incontinence episodes. Voided volume was also 
signiﬁ  cantly increased in the transdermal oxybutynin group 
(Dmochowski et al 2002). Also, signiﬁ  cant improvement 
in quality of life as measured by the Incontinence Impact 
Questionnaire and the Urinary Distress Index occurred in the 
transdermal oxybutynin group when compared to placebo. In 
patients who never received antimuscarinic treatment, trans-
dermal oxybutynin reduced weekly incontinence episodes 
by 19, comparable to oral formulations without concomitant 
antimuscarinic side effects.
In phase III trials, a pooled analysis of the transdermal 
oxybutynin 3.9 mg/day reduced the median number of 
incontinence episodes by 75% versus a 50% reduction in 
the placebo group. There was also a decrease in urinary 
frequency of 18% with transdermal oxybutynin versus 8.7% 
with placebo (p = 0.0023). Also, urinary voided volume 
was increased by 15% with the active transdermal patch 
compared to 3.6% with placebo (p  0.00001) (Dmochowski 
et al 2005). Similar ﬁ  ndings were noted when transdermal 
oxybutynin was compared with oral tolterodine long-acting 
formulation and placebo where mean daily urge incontinence 
episodes and micturition frequency decreased (Dmochowski 
et al 2003). In this trial the most common adverse events with 
the oxybutynin transdermal delivery system included local 
skin irritation such as erythema (5.6%) and pruritis (16.8%) 
(Dmochowski et al 2005). This was most likely caused by 
adhesive removal of the stratum corneum or deeper layers, 
oxybutynin, the triacetin used as a permeation enhancer, 
occlusion of the skin or some combination of these factors 
(Staskin, 2003). Overall there was no signiﬁ  cant difference 
in anticholinergic side effects in the transdermal oxybutynin 
versus placebo group with respect to: dry mouth (7% vs 5.3%, 
p = 4303); constipation (2.1% vs 2.0%, p = 9843); dizziness 
(0.8% vs 1.2%, p = 6631); abnormal vision 1.2% vs 
0.8%, p = 6431); somnolence (0.8% vs 0.4%, p = 5553); 
and nausea (1.2% vs 0.8%, p = 6631) (Dmochowski et al 
2005). The rates of discontinuation due to adverse events 
were11.2% versus 1.2% in the oxybutynin transdermal group 
versus placebo group, respectively. Although dry mouth is 
a common cause of discontinuation of oral anticholinergics, 
no participant on transdermal oxybutynin withdrew from 
these two pooled studies because of dry mouth. The lack of 
persistence in the transdermal oxybutynin group was due 
primarily to skin reactions (Dmochowski et al 2005). Most 
antimuscarinics were associated with a signiﬁ  cant incidence 
of dry mouth except oxybutynin transermal, oxybutynin 
IR 5 to 7.5 mg/day, and propiverin IR 45 mg/day compared 
with placebo. However, the latter two formulations had a 
low number of subjects. Further, comparator trials revealed 
transdermal oxybutynin was associated with less constipation 
relative to oxybutynin IR (Chapple et al 2005). On the other 
hand, site reaction such as pruritis, vesicles, and rash were 
signiﬁ  cant causes of lack of patient persistence on trans-
dermal oxybutynin (Chapple et al 2005). These reactions 
may have been avoided with rotation of site application of 
the patch. Also, increased patient discontinuation (10.7%) 
relative to that of tolteradine (1.6%) could have been 
related to the uncharacteristic nature of the site reaction Patient Preference and Adherence 2008:2 353
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versus predictable systemic effects associated with most 
antimuscarinics (Chapple et al 2005). Although transdermal 
appears to have less reported adverse reactions, most studies 
were not powered for adverse events or statistical testing was 
performed speciﬁ  cally for dry mouth.
Patient-focused perspectives 
and quality of life
Health-related quality of life and degree of functional 
impairment and bother are significant issues in the 
management of overactive bladder syndrome Patient 
perceptions of OAB impact health seeking behaviors 
and may have a great deal to do with age, gender, care-
giver/family, or physician perceptions (Marschall-Kehrel 
et al 2006). However, quality-of-life questionnaires are 
valuable instruments for determining the impact of OAB 
on patients’ quality of life before and after treatment. When 
administered after treatment these instruments may more 
accurately demonstrate the effect of successful treatment 
than other methods such as voiding diaries and records of 
urinary frequency. The positive effects of antimuscarinic 
agents on health related quality of life (HRQOL) in patients 
with OAB has recently been reported in a meta-analysis 
of placebo-controlled trials using the Kings Health Ques-
tionnaire (KHQ) which showed that clinically meaningful 
changes were associated with a 5 point change from 
baseline in the individual domain scores which were asso-
ciated with signiﬁ  cant changes in the effect size. However, 
this was done only for tolterodine IR and tolterodine ER 
(Chapple et al 2005). This is a meta-analysis of 57 trials, 25 of 
which demonstrated the true treatment beneﬁ  t and improved 
quality of life with antimuscarinic treatment. Collective data 
of 4 antimuscarinics that included transdermal oxybutynin 
demonstrated signiﬁ  cant mean score changes favoring anti-
muscarinics in 73% of HRQOL domains. Improvement in 
sleep and energy, physical activities, emotions, and relation-
ships HRQOL domains were signiﬁ  cantly improved over 
placebo (Khullar et al 2006).
The MATRIX (Muticenter Assessment of TRansdermal 
therapy In overactive bladder with transdermal oxybu-
tynin (Sand et al 2007) was an open-label, randomized, 
community-based, prospective study in which all subjects 
received 3.9 mg/day of transdermal oxybutynin applied 
twice weekly for up to 6 months. Quality of life and depres-
sion were assessed in 2878 patients during clinic visits at 
baseline, after 3 months and after 6 months of treatment 
using the KHQ and the Beck Depression Inventory II 
(BDI-II). Subjects were signiﬁ  cantly affected by their OAB 
symptoms according to a 6-point Likert global subjective 
response scale. Seventy-eight percent of subjects rated their 
OAB syndrome as a moderate to severe problem at base-
line. Responses to the KHQ revealed that 57.4% of patients 
said their social life was affected and 41.4% reported that 
OAB interfered with their social activities However, after 
treatment with transdermal oxybutynin quality of life was 
signiﬁ  cantly improved as measured by the KHQ. Nine 
of the 10 domains of the KHQ showed statistically sig-
niﬁ  cant improvement at 6 months compared to baseline. 
In men speciﬁ  cally, HRQOL signiﬁ  cantly improved in 
8 or 10 domains by 6 months. These results were clinically 
relevant as demonstrated by mean score changes exceeding 
the 3- to 5-point minimally important difference threshold 
(Kelleher 2004). Domains that were most signiﬁ  cantly 
improved included Incontinence Impact, Symptom Sever-
ity, Role and Physical Limitations, as well as Sleep/Energy. 
Improvement was reported for all individual response items 
within each domain as well. These results demonstrate the 
multidimensional impact of OAB on quality of life mea-
sures and its responsiveness to treatment with transdermal 
oxybutynin. The KHQ will be included as a component of 
the new International Consultation on Incontinence modu-
lar questionnaires because of it is fast and simple enough 
for routine clinical use. The Beck Depression Inventory 
was used to assess depression. Beck Depression Inventory 
(BDI-II) scores were signiﬁ  cantly improved from baseline 
in men within this trial (Staskin 2008). Baseline BDI-II 
summary scores 12 (which are associated with clinical 
depression) decreased from 23.9% to 17.9% (p = 0.0055).
In a randomized, double-blind, placebo-controlled, 
multicenter trial transdermal oxybutynin dose-ﬁ  nding study 
of 637 Japanese subjects with OAB, it was determined that 
a 30% reduction in incontinence frequency constituted a 
minimally important clinical difference after treatment. 
Speciﬁ  cally, a change in incontinence episodes of more 
than 3 times per week was also demonstrated to be the 
minimal clinically meaningful difference needed to produce 
improvements in health-related quality of life (Homma and 
Kawabe 2006; Homma and Koyama 2006). The average 
number of urge urinary incontinence episodes with 3.9 mg/m2 
transdermal decreased from 20.8 at baseline to 6.3 after treat-
ment (p = 0.014) (Homma and Koyama 2006). Clinically 
signiﬁ  cant changes for all KHQ domain scores were noted 
for the transdermal oxybutynin group when compared to the 
placebo group in this study.
Sexual function, as a quality of life measure and the 
effects of OAB on sexual function has been poorly studied. Patient Preference and Adherence 2008:2 354
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Yip et al (2003) found that women with detrusor overactivity 
had signiﬁ  cant deterioration of their marital relationships 
which was inversely associated with sexual satisfaction 
compared to those given placebo. Detrusor overactivity 
was more negatively associated with sexual function 
compared to stress urinary incontinence (Gordon et al 
1999). Other studies have shown that incontinent women, 
especially women with mixed urinary incontinence, have 
worse sexual function and quality of life (Temml et al 2000; 
Yip et al 2003). The impact of OAB on sexual function 
was examined in the MATRIX trial both before and after 
treatment with transdermal oxybutynin (Sand et al 2006a). 
In this trial, 569 (22.8%) participants admitted to leakage of 
urine during intercourse at baseline; whereas 438(19.3%) 
leaked with intercourse after treatment. A 12.6% improve-
ment in leakage during intercourse occurred while 
worsening of leakage during coitus occurred in 7.5% of sub-
jects (p  0.0001). The MATRIX study also demonstrated 
that 52.1% of women with OAB had decreased interest in 
sex, with 17.2% reporting a complete loss of interest. This 
complete loss of interest in sex was associated with older 
age, female gender, prolonged OAB symptoms, history of 
prior OAB therapy, and menopausal status in the female 
respondents (p = 0.0312). For male participants predictors 
of loss of interest in sex included age (p = 0.0283) and 
duration of OAB symptoms (p = 0.0312) on multivariate 
analysis. However, twice as many participants showed 
improvement in their interest in sex compared to those 
that worsened after 6 months of treatment with transdermal 
oxybutynin (23.4% versus 12.2%, p  0.0.0001) (Sand et al 
2006a). Relationships with their partners were improved in 
444/2269 (19.6%) versus 271 of subjects (11.9%) who had 
worsening of their relationships (p  0.0001).
Further analysis of the MATRIX study demonstrated 
improvements in work productivity as measured by the 
Work Productivity Questionnaire (WPQ) (Sand et al 
2006b) was presented at the 31st Annual Meeting of the 
International Urogynecological Association in Athens, 
Greece in September 2006. WPQ index data were available 
for 697/2878 participants at the end of the study and 
was found to be significantly improved from baseline 
(8.2 to 5.5, p  0.0001). Further, this study also revealed that 
treatment with transdermal oxybutynin improved nocturia 
and related symptoms. Baseline KHQ scores revealed that 
97.6% of patients were affected by nocturia and 32.9% by 
nocturnal enuresis. Working individuals were signiﬁ  cantly 
impacted; worsening nocturia was associated with signiﬁ  cant 
impairment on WPQ scales. Nocturia improved in 41% of 
subjects and worsened in 10.1% and nocturnal enuresis 
improved in 17.3 and worsened in 10.2% (p  0.0001). 
At the end of the study, all mean WPQ scale scores were 
also signiﬁ  cantly improved from baseline.
Conclusion
OAB is a symptom complex including urgency with or 
without urge urinary incontinence and commonly associ-
ated with frequency and nocturia. OAB is more prevalent 
in the elderly but has been found to permeate all age groups 
with consequent deleterious effects on quality of life. 
Sexual dysfunction, decreased work productivity, sleep 
disturbances, and social isolation are a few consequences 
of this disturbing syndrome. Fear of embarrassment leads 
to social isolation and adaptive behaviors such as avoid-
ing travel or social activities. The association of OAB 
with other co-morbidities such as diabetes, hypertension, 
depression, and fractures often exacerbates the impact of 
OAB on daily functioning. Further, economic burden and 
other health related consequences conﬁ  rm that treatment 
is imperative.
Although treatment with behavioral therapy is adequate 
for many, greater success is obtained if behavioral therapy 
is combined with pharmacotherapy. Antimuscarinic 
medications have been widely used to treat these symp-
toms for over four decades. Oxybutynin has been the most 
widely used of the antimuscarinic agents and is available 
in several formulations. Untoward side effects of oral 
formulations provided an impetus for the development 
of a transdermal oxybutynin, which reduces side effects 
and has equal efﬁ  cacy and tolerability. With transdermal 
oxybutynin there is limited impact on salivary production 
which minimizes dry mouth. Skin reactions are commonly 
cited as reasons for lack of patient persistence on transder-
mal oxybutynin which can often be avoided by alternating 
the application site. HRQOL is an important measure of 
treatment success. Transdermal oxybutynin has been shown 
to signiﬁ  cantly improve HRQOL, sexual function, marital 
relationships, as well as to enhance work productivity in 
a multicenter study of 2878 men and women of all ages. 
Transdermal oxybutynin is an appropriate ﬁ  rst line treat-
ment of OAB, particularly in patients who are on multiple 
medications and have signiﬁ  cant side effects on other 
antimuscarinic agents.
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